Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ORAVESCENT Fentanyl · 6 trials · 8 indications
| Name | Type | Description |
|---|---|---|
| OraVescent Fentanyl | DRUG | - |
| ORAVESCENT Fentanyl Citrate | DRUG | - |
| OraVescent fentanyl (OVF) | DRUG | - |
Inclusion Criteria: Patients are included in the study if all of the following criteria are met: * The patient is willing to provide written informed consent to participate in this study. * The patient is 18 through 80 years of age. * Women must be surgically sterile, 2 years postmenopausal, or, i...
Top 20 of 25 competitors
ORAVESCENT Fentanyl is an investigational small molecule being developed for the management of breakthrough pain in opioid-tolerant patients. It has been studied in conditions including chronic low back pain, chronic neuropathic pain, and cancer-related pain. The drug is in Phase 3 clinical development.
ORAVESCENT Fentanyl is a small molecule that targets opioid receptors. It is designed to provide rapid pain relief for breakthrough pain episodes. The drug is being studied in opioid-tolerant patients with chronic pain conditions.
ORAVESCENT Fentanyl is being developed by Teva Pharmaceutical Industries Limited, which trades under the ticker TEVA. The company is conducting Phase 3 clinical trials to evaluate the drug's efficacy and safety for breakthrough pain management.
ORAVESCENT Fentanyl is in Phase 3 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The completed Phase 3 trials studied its use in breakthrough pain associated with cancer, chronic low back pain, and chronic neuropathic pain.
ORAVESCENT Fentanyl has completed three Phase 3 trials: NCT00105937 in cancer pain, NCT00214942 in chronic low back pain, and NCT00214955 in chronic neuropathic pain. A fourth trial, NCT00343733, studied noncancer-related chronic pain. All trials were conducted in the United States.
ORAVESCENT Fentanyl is a formulation of fentanyl citrate, as indicated by the trial titles for NCT00214942, NCT00214955, and NCT00343733. It is an investigational product being developed for breakthrough pain management in opioid-tolerant patients.